SOPH — SOPHiA GENETICS Reports Third‑Quarter 2026 Results (Confirmed)

What happened

SOPHiA GENETICS (SOPH) issued a third‑quarter 2026 results announcement today; the SMC digest captured the company’s earnings release (company IR link: https://ir.sophiagenetics.com/2026-11-03-SOPHiA-GENETICS-Reports-Third-Quarter-2026-Results). The firm’s press feed also contains a collaboration announcement with Synnovis about bringing blood‑based cancer testing to patients in the U.K. (https://www.sophiagenetics.com/news/synnovis-and-sophia-genetics-collaborate). Both items appear in the supplied news market data.

Sources: S1 · S2

Why it matters

An issuer earnings release is a direct, headline catalyst for SOPH shares and options — reported revenue, EPS, guidance or material commentary can move price and implied volatility. Traders should (1) open the IR release to confirm line‑item figures and any guidance, (2) reconcile totals if component figures are published, and (3) use price, volume and options flow for tape confirmation before sizing event trades. Do not assume a beat/miss without the company’s published numbers.

Sources: S3 · S2

What remains uncertain

• The supplied market data confirm the existence of today’s Q3 earnings release but do not include the actual line‑item financial metrics or guidance; open the linked IR release to read the reported figures.